A Single-arm, Single-center Prospective Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma Patients
Latest Information Update: 24 Jul 2023
At a glance
- Drugs Catequentinib (Primary) ; Toripalimab (Primary)
- Indications Malignant fibrous histiocytoma
- Focus Therapeutic Use
Most Recent Events
- 13 Sep 2022 Results of preliminary analysis assessing the efficacy and safety of anlotinib combined with toripalimab in the first-line treatment of patients with unresectable or metastatic UPS presented at the 47th European Society for Medical Oncology Congress
- 08 Jul 2019 Planned End Date changed from 19 Jun 2023 to 19 Jul 2023.
- 08 Jul 2019 Planned primary completion date changed from 19 Jun 2022 to 19 Jul 2022.